355 related articles for article (PubMed ID: 12882847)
21. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Berger ED; Bader BD; Ebert C; Risler T; Erley CM
J Hypertens; 2002 Apr; 20(4):739-43. PubMed ID: 11910311
[TBL] [Abstract][Full Text] [Related]
22. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Sato A; Tabata M; Hayashi K; Saruta T
Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
[TBL] [Abstract][Full Text] [Related]
23. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
Robles NR; Fernandez Carbonero E; Romero B; Sánchez Casado E; Cubero JJ
Cardiovasc Ther; 2009; 27(2):101-7. PubMed ID: 19426247
[TBL] [Abstract][Full Text] [Related]
24. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Nielsen FS; Rossing P; Gall MA; Skøtt P; Smidt UM; Parving HH
Diabetes; 1997 Jul; 46(7):1182-8. PubMed ID: 9200654
[TBL] [Abstract][Full Text] [Related]
25. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria.
Kincaid-Smith P; Fairley K; Packham D
Nephrol Dial Transplant; 2002 Apr; 17(4):597-601. PubMed ID: 11917051
[TBL] [Abstract][Full Text] [Related]
26. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy.
Tarnow L; Rossing P; Jensen C; Hansen BV; Parving HH
Diabetes Care; 2000 Dec; 23(12):1725-30. PubMed ID: 11128341
[TBL] [Abstract][Full Text] [Related]
27. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
[TBL] [Abstract][Full Text] [Related]
28. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
29. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria.
Morgan T; Anderson A; Bertram D; MacInnis RJ
J Renin Angiotensin Aldosterone Syst; 2004 Jun; 5(2):64-71. PubMed ID: 15295717
[TBL] [Abstract][Full Text] [Related]
30. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
[TBL] [Abstract][Full Text] [Related]
32. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.
Andersen NH; Poulsen PL; Knudsen ST; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Mogensen CE
Diabetes Care; 2005 Feb; 28(2):273-7. PubMed ID: 15677778
[TBL] [Abstract][Full Text] [Related]
33. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Tan F; Mukherjee JJ; Lee KO; Lim P; Liew CF
Singapore Med J; 2010 Feb; 51(2):151-6. PubMed ID: 20358155
[TBL] [Abstract][Full Text] [Related]
34. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Christensen PK; Lund S; Parving HH
Kidney Int; 2001 Oct; 60(4):1435-42. PubMed ID: 11576357
[TBL] [Abstract][Full Text] [Related]
35. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
[TBL] [Abstract][Full Text] [Related]
36. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Rossing K; Schjoedt KJ; Jensen BR; Boomsma F; Parving HH
Kidney Int; 2005 Sep; 68(3):1190-8. PubMed ID: 16105050
[TBL] [Abstract][Full Text] [Related]
37. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD
J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893
[TBL] [Abstract][Full Text] [Related]
38. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.
Hollenberg NK; Price DA; Fisher ND; Lansang MC; Perkins B; Gordon MS; Williams GH; Laffel LM
Kidney Int; 2003 Jan; 63(1):172-8. PubMed ID: 12472780
[TBL] [Abstract][Full Text] [Related]
39. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
40. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
